Immune response treated with bone marrow mesenchymal stromal cells after stroke

Stroke is a leading cause of death and long-term disability worldwide. Tissue plasminogen activator (tPA) is an effective treatment for ischemic stroke. However, only a small part of patients could benefit from it. Therefore, finding a new treatment is necessary. Bone marrow mesenchymal stromal cells (BMSCs) provide a novel strategy for stroke patients. Now, many patients take stem cells to treat stroke. However, the researches of the precise inflammatory mechanism of cell replacement treatment are still rare. In this review, we summarize the immune response of BMSCs treated to stroke and may provide a new perspective for stem cell therapy.

Automated summary

Stroke is a major cause of death and disability worldwide, and current treatment options are limited. Bone marrow mesenchymal stromal cells (BMSCs) offer a new approach for stroke treatment, but research on the precise inflammatory mechanism is lacking. In this review, we summarize the immune response of BMSCs in stroke treatment and provide a new perspective for stem cell therapy.